Omar Fadhli, MD
Otolaryngology · Kissimmee, FLNPI 1922160951
Payments from drug & device makers
What this record shows
This record is dominated by other: $1,505 of the $2,264 with a category attached, or 66.5%. Olympus America Inc. accounts for 67.9% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2024 at $1,611 and has fallen 87.7% since, to $198 in 2025.
Across 36 payments — averaging $62.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus America Inc.$2K
- Astellas Pharma US Inc$172
- Stryker$128
- GSK$106
- Medtronic$103
- Integra Lifesciences Corporation$48
- plus $170 from 7 others
What the payments were for
- Food & beverage$75934%
- Other$1,50566%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus America Inc. | 3 | $1,537 |
| Astellas Pharma US Inc | 8 | $172 |
| Stryker | 5 | $128 |
| GSK | 5 | $106 |
| Medtronic | 5 | $103 |
| Integra Lifesciences Corporation | 2 | $48 |
| Acclarent, Inc | 2 | $42 |
| Phadia US Inc. | 1 | $27 |
| Merck | 1 | $24 |
| Aerin Medical Inc. | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Smith+Nephew | 1 | $18 |
How this compares
$2,264 in reported general payments places this provider in the 60th percentile of 586 otolaryngology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azelastine Hcl | 141 | $3,447 |
| Fluticasone Propionate | 201 | $1,995 |
| Famotidine | 192 | $1,799 |
| Mometasone Furoate | 23 | $1,357 |
| Ipratropium Bromide | 18 | $933 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 48 | $473 |
| Levocetirizine Dihydrochloride | 37 | $464 |
| Doxycycline Hyclate | 31 | $301 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 39 | $300 |
| Montelukast Sodium | 13 | $272 |
| Nystatin | 13 | $239 |
| Ciprofloxacin Hcl | 17 | $179 |
| Ofloxacin | 14 | $172 |
| Pantoprazole Sodium | 25 | $154 |
| Mupirocin | 27 | $146 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Kissimmee
- Cecelia DamaskOrlando$707K
- Ralph TufanoSarasota$469K
- Franklin RimellFort Myers$314K
- David BrodnerBoynton Beach$209K
- Maria SuurnaMiami$189K
- Jane DillonOrmond Beach$180K
- Jeb JusticeGainesville$142K
- Indranil DebnathWinter Park$109K
- Agustin ArrietaMiami$95K
- John WestineGainesville$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.